Efficacy and safety of cefovecin (Convenia) for the treatment of urinary tract infections in dogs.
OBJECTIVE
To determine the efficacy and safety of cefovecin (Convenia); Pfizer Animal Health) in the treatment of urinary tract infections in dogs.


METHODS
A multi-centre, blinded, randomised study was conducted in 129 dogs with urinary tract infections. Cephalexin (Rilexine) administered twice daily at 15 mg/kg bodyweight orally for 14 days was compared with a single, subcutaneous injection of cefovecin (Convenia) in dogs. The primary efficacy parameter assessed was bacterial elimination of the pretreatment uropathogen.


RESULTS
One hundred and twenty-nine dogs were included in efficacy assessments. Escherichia coli was eliminated in 90.5 per cent of cefovecin-treated dogs compared with 52.9 per cent of cephalexin-treated dogs (P=0.0004). Overall cure rates for dogs with Escherichia coli infections were 79.1 per cent for cefovecin and 36.4 per cent for cephalexin-treated dogs (P=0.0003). There were no suspected adverse drug reactions attributed to treatment with cefovecin or cephalexin.


CONCLUSIONS
Cefovecin was shown to be an effective and safe treatment for urinary tract infections.
Passmore
C A
CA
Pfizer Animal Health, Pfizer Ltd, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK.
Sherington
J
J
Stegemann
M R
MR
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D004285:Dogs; D004311:Double-Blind Method; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000662:veterinary*; D005060:Europe; D005260:Female; D007279:Injections, Subcutaneous / Q000662:veterinary; D008297:Male; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000662:veterinary*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C516253:cefovecin